Blume Capital Management Boosts Stake in UnitedHealth by 954%

Blume Capital Management Inc. has significantly increased its investment in UnitedHealth Group Incorporated (NYSE: UNH), acquiring an additional 2,777 shares during the second quarter of 2023. This move raised Blume’s total holdings to 3,068 shares, reflecting a remarkable increase of 954.3%. According to the firm’s latest filing with the Securities and Exchange Commission, these shares were valued at approximately $957,000.

Other institutional investors have also been actively adjusting their positions in UnitedHealth Group. Brighton Jones LLC raised its stake by 176.2% in the fourth quarter, now holding 44,249 shares worth about $22.4 million after acquiring 28,231 additional shares. Similarly, Revolve Wealth Partners LLC increased its position by 137.1%, now owning 4,019 shares valued at $2.03 million following a purchase of 2,324 shares.

GAMMA Investing LLC and Walkner Condon Financial Advisors LLC also reported growth in their stakes, with GAMMA increasing its holdings by 7.4% to 15,838 shares worth $8.3 million, and Walkner Condon adding 4.2% to own 890 shares valued at $466,000. Foundation Wealth Management LLC PA completed this trend by lifting its position by 6.9%, now owning 1,765 shares worth $925,000.

As of now, institutional investors collectively control approximately 87.86% of UnitedHealth Group’s stock, underscoring the company’s strong appeal among large investment firms.

Market Performance and Dividend Announcement

On Wednesday, UnitedHealth Group’s shares opened at $365.47. Over the past year, the stock has experienced a low of $234.60 and a high of $630.73. The company boasts a market capitalization of $331 billion and maintains a price-to-earnings (P/E) ratio of 15.83, along with a P/E/G ratio of 2.36. Its debt-to-equity ratio stands at 0.73, with both current and quick ratios at 0.85.

Recently, UnitedHealth Group declared a quarterly dividend of $2.21 per share, which was paid on September 23, 2023. Investors of record on September 15 received this payment, marking an annualized dividend of $8.84 and a yield of 2.4%. The company’s dividend payout ratio currently sits at 38.30%, indicating its commitment to returning value to shareholders.

Analyst Ratings and Future Projections

Equities research analysts have responded positively to UnitedHealth Group’s performance. Mizuho recently raised its price target from $300 to $430, rating the stock as “outperform.” Barclays also increased its target from $352 to $386, maintaining an “overweight” rating. Conversely, Baird R W changed its rating from “hold” to “strong sell,” reflecting a more cautious outlook.

The Goldman Sachs Group initiated coverage of UnitedHealth Group with a “buy” rating and a target price of $406, while JPMorgan Chase & Co. increased its target from $310 to $425, also giving it an “overweight” rating.

Currently, the stock has received 18 buy ratings, seven hold ratings, and four sell ratings, resulting in an average rating of “hold” with a target price of $385.13 according to MarketBeat.

UnitedHealth Group operates as a diversified healthcare company, divided into four segments: UnitedHealthcare, Optum Health, Optum Insight, and Optum Rx. The company provides a wide range of health benefit plans and services tailored to various demographics, including national and public sector employers, individuals, and state programs for underprivileged populations.

As UnitedHealth Group continues to attract substantial institutional investment and analysts show optimism regarding its future performance, the company remains a key player in the healthcare sector, demonstrating resilience and growth potential in a dynamic market.